In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ukraine’s Plea To Industry: Restart Clinical Trials And Give Us New ‘Weapons’ To Fight Cancer

While Existing Studies Continue, New Trials Have Dried Up

Executive Summary

More than one year into the conflict, pharma employees in Ukraine have made heroic efforts to maintain existing clinical studies – but what the country’s doctors and CROs really want is for international companies to start opening new trials again.

You may also be interested in...



Merck KGaA Overcomes Ukraine Disruption To Keep MS Frontrunner On Track

The German group is optimistic evobrutinib can be a blockbuster in multiple sclerosis and has adapted its pivotal trial to cope with disruption caused by the war in Ukraine.

Arcus And Gilead Make GI Cancers The Focus Of Their TIGIT Hopes

Gilead ups its investment in its TIGIT partner, as the firms pivot to a less crowded market opportunity in upper GI cancers.

BMS Looks For Krazati KRAS Lead After Amgen’s Stumble

Success in a confirmatory study and in combination with Keytruda could seal BMS’s best-in-class claims.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV147674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel